|
In the latest on-line version of Tissue Antigens Mats Alheim and co-workers at Karolinska Hospital, Stockholm, Sweden present data from a study with XM-ONE®. In the study CD3 and CD19 antibodies has been included in the kit enabling a crossmatch for both lymphocyte and endothelial cell antibodies. XM-ONE® including CD3 and CD19 is CE–marked and pending FDA approval.
 |
Dr. Mats Alheim
Karolinska University Hospital
Huddinge, Sweden
|
Mats Alheim: “Introducing an additional crossmatch test into the immunological workup of recipients of kidneys from deceased donors could impose logistic problems on the tissue typing laboratory. Therefore, we set out to test the possibility that the lymphocyte population obtained following isolation of cells with the XM-ONE® crossmatch test could be used to perform a flow cytometric LXM in the same tube as the flow cytometric EPCXM test.”
In the now published article, “A flow cytometric crossmatch test for simultaneous detection of antibodies against donor lymphocytes and endothelial precursor cells”, Alheim and co-workers showed that lymphocytes co-purified with EPCs can be used in LXM tests allowing simultaneous detection of Abs reactive with donor EPCs and lymphocytes. The study compared conventional LXM with T- and B-cell XM using XM-ONE for different serum-donor combinations. The channel shifts recorded on CD3 positive lymphocytes correlated very well (R²=0.94) between the two different methods. For B-lymphocytes the correlation coefficient was R²=0.71.
The only routinely available test for non-HLA antibodies
XM-ONE® is the only assay available that can be used as a clinical routine diagnostic test, which will allow the transplant community to investigate in large patient populations the extent to which non-HLA Abs is a clinically significant problem. The correlation between endothelial cell antibodies and clinical outcome was published in Transplantation February 2009 (Breimer et al) showing that patients having a positive XM-ONE® test had a significantly higher incidence of acute rejections and also a worse renal function post transplantation.
“We at AbSorber are excited about the development of XM-ONE®. Being able to do a “full” crossmatch, detecting donor specific antibodies both against HLA and non-HLA will further increase the clinical value of the test. Doing the lymphocyte and endothelial cell crossmatch in the same tube will be less time consuming and also make the work at the laboratory less cumbersome”, says Lars Öqvist, Director Marketing at AbSorber.
For information, please contact: Lars Öqvist, Director Marketing,
e-mail lars.oqvist@absorber.se, mobil +46 (0) 766 276 550.
|
